Johnson & Johnson (NYSE: JNJ) announced clinical results from two separate studies regarding its lung cancer treatments. The company presented findings from the Phase 2b COPERNICUS study and the Phase 3 PAPILLON study on Monday.
The COPERNICUS trial evaluated 214 U.S. patients with previously untreated advanced non-small cell lung cancer (NSCLC) who had common EGFR mutations. The study tested a subcutaneous combination of RYBREVANT FASPRO and LAZCLUZE. The patients received the treatment alongside prophylactic measures to mitigate blood clots and skin-related side effects. At a median follow-up of 8.3 months, 8% of participants discontinued treatment due to adverse events. Skin rash occurred in 25% of patients, while administration-related reactions and venous thromboembolism each affected 3%. The company noted that these rates were lower than those seen in the intravenous regimen tested in the Phase 3 MARIPOSA study.
Separately, Johnson & Johnson shared final overall survival results from the Phase 3 PAPILLON study. This trial evaluated intravenous RYBREVANT combined with chemotherapy against chemotherapy alone for advanced NSCLC patients with EGFR exon 20 insertion mutations. Patients on the combination regimen achieved a median overall survival of 34.3 months, compared to 27.9 months for chemotherapy alone. This represents an extension of median survival by over six months. A prespecified analysis accounting for the 76% of chemotherapy patients who crossed over to second-line RYBREVANT indicated a 43% reduction in the risk of death. The combination also extended progression-free survival through a second disease progression to 28.3 months, compared to 17.5 months for chemotherapy alone.
At the time of publication, Johnson & Johnson shares were down 0.74% to $264.35.
